Larimar Therapeutics (LRMR) Cash from Financing Activities (2013 - 2024)

Larimar Therapeutics' Cash from Financing Activities history runs 10 years deep, the most recent figure standing at $36000.0 for Q4 2024.

• Quarterly Cash from Financing Activities changed N/A year-over-year to $36000.0 in Q4 2024, while the trailing twelve-month figure through Dec 2024 was $161.9 million (up 218860.81% YoY) and the FY2025 annual result came in at $65.1 million, down 59.79% from the prior year.
• Cash from Financing Activities was $36000.0 for Q4 2024 at Larimar Therapeutics, up from $30000.0 in the prior quarter.
• Across five years, Cash from Financing Activities topped out at $162.2 million in Q1 2024 and bottomed at -$334000.0 in Q2 2024.
• A 3-year average of $28.4 million and a median of $36000.0 in 2024 frame the typical range for Cash from Financing Activities.
• Peak annual rise in Cash from Financing Activities reached 9981.05% in 2020, while the deepest fall reached 101.36% in 2020.
• Larimar Therapeutics' Cash from Financing Activities stood at $242000.0 in 2020, then tumbled by 230.58% to -$316000.0 in 2022, then soared by 111.39% to $36000.0 in 2024.
• Business Quant data shows LRMR's Cash from Financing Activities at $36000.0 in Q4 2024, $30000.0 in Q3 2024, and -$334000.0 in Q2 2024.